Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 530,600 shares, a decline of 22.7% from the November 30th total of 686,600 shares. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is presently 0.2 days. Approximately 8.5% of the shares of the company are sold short.
Biofrontera Stock Performance
Biofrontera stock traded up $0.04 during midday trading on Friday, hitting $1.11. 218,657 shares of the company’s stock were exchanged, compared to its average volume of 1,018,731. The firm’s 50 day simple moving average is $0.96 and its 200 day simple moving average is $1.04. Biofrontera has a 12-month low of $0.61 and a 12-month high of $3.90. The stock has a market cap of $8.60 million, a price-to-earnings ratio of -0.49 and a beta of 0.38.
Analyst Upgrades and Downgrades
Separately, Benchmark reissued a “buy” rating and issued a $7.00 price objective on shares of Biofrontera in a report on Friday, November 15th.
About Biofrontera
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
Read More
- Five stocks we like better than Biofrontera
- How to Read Stock Charts for Beginners
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Consumer Discretionary Stocks Explained
- Top 3 ETFs to Hedge Against Inflation in 2025
- 3 REITs to Buy and Hold for the Long Term
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
